title: Choice of drugs in the treatment of chronic hepatitis B in pregnancy.
abstract: The selection of antiviral drugs for chronic hepatitis B (CHB) treatment in pregnancy is very difficult since none of the drugs have been approved for use in pregnancy. Transmission from mother to newborn remains the most frequent route of infection in mothers with high viral load and positive hepatitis B e antigen status, even with the use of appropriate prophylaxis with hepatitis B virus (HBV) immunoglobulin and HBV vaccination. We read from the article written by Yi et al that lamivudine treatment in early pregnancy was safe and effective. However, we could not understand why adefovir dipivoxil (ADV) was used in three pregnancy cases, since ADV has been classified as pregnancy category C. In pregnancy, telbivudine or tenofovir should be selected when the treatment of CHB is necessary, since these drugs have been classified as Food and Drug Administration pregnancy risk category B.
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Guclu
authors.forename: Oguz
authors.initials: O
authors.lastname: Karabay
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019259:Lamivudine / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*
chemical_list: D000998:Antiviral Agents; D019259:Lamivudine
keywords: Adefovir dipivoxil; Chronic hepatitis B; Entecavir; Lamivudine; Pregnancy; Tenofovir; Treatment
references.citation: J Hepatol. 2011 Dec;55(6):1215-21
references.pmid: 21703206
references.citation: J Hepatol. 2011 Dec;55(6):1171-3
references.pmid: 21718670
references.citation: World J Gastroenterol. 2012 Dec 7;18(45):6645-50
references.pmid: 23236240